# UTILITY PATENT APPLICATION TRANSMITTAL LETTER

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. P239US00/ÅH/IO



## To the Assistant Commissioner for Patents:

Transmitted herewith for filing is the patent application of:
Thomas NILSSON and Lars-Gunnar NILSSON
corresponding to Swiss application No. 0003083-5, filed August 31, 2000,
entitled: METERED ELECTRO-DOSE

Enclosed are:

| | |
|---|---|
| X | 22 pages of specification. |
| X | 13 sheets of formal drawings. |
| X | a newly-executed declaration of the inventors. |
| | a copy of an executed declaration of the inventor from prior application Serial No. , filed . |
| | incorporation by reference. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied as indicated in the preceding box, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. |
| X | an assignment of the invention to Microdrug AG, including assignment cover sheet. |
| | Information Disclosure Statement with Form PTO-1449. |
| | copies of the Information Disclosure Statement citations. |
| | preliminary amendment. |
| X | return receipt postcard (MPEP 503), specifically itemized. |
| X | a verified statement to establish small entity status under 37 CFR 1.9 and 1.27. |
| | a verified statement to establish small entity status filed in prior application. Status is still proper and desired. |
| | a certified copy of the Priority Document. |
| X | other: Data Entry Sheet . |

If a CONTINUING APPLICATION, *check appropriate box and supply the requisite information.*

[ ] Continuation [ ] Divisional [ ] Continuation-in-part (CIP)

of prior application No. , filed .

| | |
|---|---|
| X | Customer No. 000466. |
| X | Correspondence address is: YOUNG & THOMPSON, 745 South 23rd Street, Second Floor, Arlington, Virginia 22202. |
| X | Telephone: (703) 521-2297. Telefax: (703) 685-0573 or (703) 979-4709. |

| **UTILITY PATENT APPLICATION TRANSMITTAL LETTER** (continued) | Docket No. P239US00/ÅH/IO |
|---|---|

**CLAIMS AS FILED**

| | NO. FILED | NO. EXTRA | RATE | FEE |
|---|---|---|---|---|
| BASIC FEE | | | $ 690 | $ 690 |
| TOTAL CLAIMS | 32 - 20 = | 12 | x$ 18 | 216 |
| INDEPENDENT CLAIMS | 3 - 3 = | 0 | x$ 78 | |
| MULTIPLE DEPENDENT CLAIM PRESENT | | | $ 260 | |
| | | | **TOTAL** | $ |
| If applicant has small entity status under 37 CFR 1.9 and 1.27, then divide total fee by 2, and enter amount here. | | | **SMALL ENTITY TOTAL** | $ 561 |

| | |
|---|---|
| X | A check in the amount of $601 to cover the filing fee is enclosed. |
| X | The Commissioner is hereby authorized to charge indicated fees and credit any over-payments to Deposit Account No. 25-0120 in the name of Young & Thompson, as described below. A duplicate copy of this sheet is enclosed. |
| | Charge the amount of $ as filing fee. |
| X | Credit any overpayment. |
| X | Charge any additional fee required under 37 CFR 1.16 and 1.17, during the pendency of this application. |
| | Charge the issue fee set in 37 CFR 1.18 at the mailing of the Notice of Allowance. |

Benoît Castel

Benoît Castel
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
Telephone 703/521-2297

September 18, 2000

Form B

**VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN**

Docket Number (Optional): P239US00/AH/IO

Applicant or Patentee: MICRODRUG AG
Serial or Patent No.:
Filed or Issued: herewith
Title: Metered electro-dose

I hereby declare that I am

☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN MICRODRUG AG
ADDRESS OF SMALL BUSINESS CONCERN Landweg 1, CH-6052 HERGISWIL NW, Switzerland

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

☐ the specification filed herewith with title as listed above.
☒ the application identified above.
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights in the invention must file separate verified statements averring to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

☒ no such person, concern, or organization exists.
☐ each such person, concern or organization is listed below.

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING John Brehmer
TITLE OF PERSON IF OTHER THAN OWNER Vice president
ADDRESS OF PERSON SIGNING Landweg 1, CH-6052 HERGISWIL NW, Switzerland
SIGNATURE _____ DATE 2000-09-11

INVENTOR INFORMATION

| | |
|---|---|
| Inventor One Given Name:: | THOMAS |
| Family Name:: | NILSSON |
| Postal Address Line One:: | HÅGAVÄGEN 3 |
| City:: | MARIEFRED |
| Country:: | SWEDEN |
| City of Residence:: | MARIEFRED |
| Country of Residence:: | SWEDEN |
| Postal or Zip Code:: | SE-647 32 |
| Citizenship Country:: | SWEDEN |

| | |
|---|---|
| Inventor Two Given Name:: | LARS-GUNNAR |
| Family Name:: | NILSSON |
| Postal Address Line One:: | ESPLANADEN 15E |
| City:: | KÖPING |
| Country:: | SWEDEN |
| City of Residence:: | KÖPING |
| Country of Residence:: | SWEDEN |
| Postal or Zip Code:: | SE-731 30 |
| Citizenship Country:: | SWEDEN |

CORRESPONDENCE INFORMATION

| | |
|---|---|
| Correspondence Customer Number:: | 000466 |
| Name Line One:: | YOUNG & THOMPSON |
| Address Line One:: | 745 SOUTH 23RD STREET |
| Address Line Two:: | SECOND FLOOR |
| City:: | ARLINGTON |
| State or Province:: | VIRGINIA |
| Country:: | U.S.A. |
| Postal or Zip Code:: | 22202 |
| Telephone:: | 703-521-2297 |
| Fax One:: | 703-685-0573 |
| Fax Two:: | 703-979-4709 |

APPLICATION INFORMATION

| | |
|---|---|
| Title Line One:: | METERED ELECTRO-DOSE |
| Total Drawing Sheets:: | 13 |
| Formal Drawings?:: | Yes |
| Application Type:: | UTILITY |
| Docket Number:: | P239US00/ÅH/IO |

REPRESENTATIVE INFORMATION

Representative Customer Number:: 000466

PRIOR FOREIGN APPLICATION

| | |
|---|---|
| Foreign Application One:: | 0003082-5 |
| Filing Date:: | AUGUST 31, 2000 |
| Country:: | SWEDEN |
| Priority Claimed:: | Yes |

**Metered electro-dose**

## TECHNICAL FIELD

The present invention relates to electrostatic dosing and more particularly to an electro-dose using electro-powder as well as a process and a method for preparation of a metered electro-dose for inhalation into the deep or upper lungs by means of an inhaler device.

## BACKGROUND

The dosing of drugs is carried out in a number of different ways in the medical service today. Within health care more and more is focused on the possibility of dosing medical drugs as a powder directly to the airways and lungs of a patient by means of an inhaler in order to obtain an effective, quick and patient-friendly administration of such substances.

A dry powder inhaler, DPI, represents a device intended for administration of powder into the deep or upper lung airways by oral inhalation. With deep lung should be understood the peripheral lung and alveoli, where direct transport of active substance to the blood can take place. Particle sizes, to reach into the deep lung, should be in a range 0.5 - 3 μm and for a local lung delivery in the range 3 - 5 μm. A larger grain size will easily stick in the mouth and throat, and a smaller grain size may accompany the expiration air out again.

To succeed with systemic delivery of medical powders to the deep lung by inhalation there are some criteria, which have to be fulfilled. The most important is a very high degree of de-agglomeration of the medical powder but also an exact dose is of great importance. This is not possible with dry powder inhalers of today without special arrangements as for example a so called spacer.

By means of a spacer the small grains are evenly distributed in a container from which the inhalation can take place. Upon inhalation from the spacer the fine powder floating free in the air will effectively reach the alveoli of the

lung. This method in principle has two drawbacks, firstly difficulties to control the amount of medicine emitted to the lung as an uncontrolled amount of powder sticks to the walls of the spacer and secondly difficulties in handling the relatively space demanding apparatus.

Powders for inhalers have a tendency of agglomerating, in other word to clod or to form small or larger lumps, which then have to be de-agglomerated. De-agglomeration is defined as breaking up agglomerated powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-agglomeration is performed as a stage one during dosing and as a final stage two during the patient's inspiration through the DPI.

Inhaler devices normally use the force exerted by the patient's more or less normal inspiration effort for de-agglomerating the medical substance administered when inhaling in an effort to bring as much as possible of the active substance into the lungs. This often leads to inhaler designs using high pressure drops, which will put the patient's lungpower to the test.

One major problem with some of the technique described above is to also obtain a low relative standard deviation (RSD) between doses with this type of technique due to lack of in line control possibilities in production making it hard to be in compliance with regulatory demands.

As already noted for an optimum amount of substance to reach the alveoli, an administered powder dose should preferably have a grain size between 0.5 and 3 μm. Besides, the inspiration must take place in a calm way to decrease air speed and thereby reduce deposition in the upper respiratory tracts.

Technologies to de-agglomerate today include advanced mechanical and aerodynamic systems and combinations between electrical and mechanical filling systems that can be seen in for instance in U.S. Patent No. 5,826,633. Further there are systems disclosed for dispersing aerosolized doses of

medicaments, e.g. U.S. Patent No. 5,775,320, U.S. Patent No. 5,785,049, and U.S. Patent No. 5,740,794. Furthermore, in our International Publications WO 00/0636 and WO 00/6235 principles for de-agglomeration and classification are disclosed.

The term electro-powder refers to a micronized medical powder presenting controlled electrostatic properties to be suitable for electrostatic administration in an inhaler device. Such an electro-powder provides possibilities for a better dosing from electrostatically operating equipment such as disclosed in our U.S. Patent No. 6,089,227 as well as our Swedish Patents No. 9802648-7 and 9802649-5, which present excellent inhalation dosing performance.

The state of the art also discloses a number of solutions for depositing powder for dosing. U.S. Patent No. 6,063,194 discloses a powder deposition apparatus for depositing grains on a substrate using an electrostatic chuck having one or more collection zones and using an optical detection for quantifying the amount of grains deposited. U.S. Patent No. 5,714,007 and U.S. patent No. 6,007,630 disclose an apparatuses for electrostatically depositing a medicament powder upon predefined regions of a substrate, the substrates being used to fabricate suppositories, inhalants, tablet capsules and the like. In U.S. Patent No. 5,699,649 and U.S. Patent No. 5,960,609 are presented metering and packaging methods and devices for pharmaceuticals and drugs, the methods using electrostatic phototechnology to package microgram quantities of fine powders in discrete capsule and tablet form.

Devices of prior art technology does often not reach a sufficiently high degree of de-agglomeration and an exact dose is not well developed and leaves much to be desired when it comes to dosage conformity and lung deposition effectiveness of the medical substance. Therefore, there is still a demand of pre-fabricated high accuracy pre-metered doses to be loaded into an inhaler device, which then will ensure repeated exact doses to be given. The active dry powder then must possess a fine particle fraction, which guarantees its

administration to a position within the lung of a patient where it will exert its expected effect.

## SUMMARY

An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a pre-metered medical powder intended for use in a dry powder inhaler and is formed from an electro-powder constituting an active powder substance or a dry powder medical formulation being onto a device member forming a dose carrier. The electro-dose prepared from an electro-powder presenting a fine particle fraction (FPF) having of the order 50 % or more of its content with a particle size between 0.5-5 μm. The electro-powder of such a pre-metered electro-dose further provides electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 μC/g and presents a charge decay rate constant $Q_{50}$ of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity $a_w$ of less than 0.5.

The electro-dose porosity is adjusted by means of a mechanical and/or electrical vibration of the dose receiving device member during the electro-dose build-up operation to obtain an optimized porosity value of 75 to 99.9% calculated as $100 - 100\times(\text{Density}_{\text{electro-dose}}/\text{Density}_{\text{electro-powder}})$. A number of parameters must be kept under strict control during the processing in order to obtain the desired electro-dose for utilization in a dry powder inhaler.

An electro-dose according to the present invention is set forth by the independent claim 1 and the dependent claims 2 to 7. Furthermore a method for obtaining an electro-dose is set forth by the independent claim 8 and further embodiments of the method are set forth by the dependent claims 9 to 21. Also a process for the manufacturing of an electro-powder is set forth by the independent claim 22 and the dependent claims 23 to 31.

## SHORT DESCRIPTION OF THE DRAWINGS

The invention, together with further objects and advantages thereof, may best be understood by making reference to the following description taken together with the accompanying drawings, in which:

FIG. 1 is a simplified flow chart for creating an electro-dose from an electro-powder;

FIG. 2 is a flow chart illustrating the powder dose analysis when preparing the electro-dose;

FIG. 3 is a summary flow chart illustrating preparation of the electro-dose;

FIG. 4 illustrates a cross section of a dose carrier provided with a conducting or dissipative sheet for the preparation of an electro-dose by electrostatic methods;

FIG. 5 illustrates a cross section of a dose carrier made from a conductive or dissipative material for the preparation of an electro-dose by electrostatic methods;

FIG. 6 illustrates a cross section of a dose carrier containing a buried conductive material sheet inside an isolative material for the preparation of an electro-dose by means of electrostatic methods;

FIG. 7 illustrates a cross section of a dose carrier containing several separate buried conductive material sheets for the preparation of an electro-dose by electrostatic methods;

FIG. 8 illustrates transfer of electro-powder to a carrier by means of an electrostatic field;

FIG. 9 illustrates transfer of electro-powder to the carrier by means of an electrostatic field and a focussing means;

FIG. 10 illustrates a control circuitry utilized in the transfer of powder according to FIG. 9;

FIG. 11 illustrates an applied alternating electric field as function of time in transferring powder particles to the carrier;

FIG. 12 illustrates displacement of carrier surface in micrometers as a function of time;

FIG 13 illustrates a "tree" structure in an enlarged view initial positioning of de-agglomerated particles at the carrier surface;

FIG. 14 illustrates a "sponge" structure in an enlarged view of particles positioned at the carrier surface after a compaction operation;

FIG. 15 illustrates in an enlarged view of a "velvet" structure of the particles at the carrier surface;

FIG. 16 is graph representing dose porosity and de-agglomeration for particles of sizes 3 and 5 micrometers;

FIG. 17 is a graph representing calculation of de-agglomeration for particles up to 3 micrometers from an initial electro-powder particle size;

FIG. 18 is a graph representing calculation of de-agglomeration for particles up to 5 micrometers from an initial electro-powder particle size; and

FIG. 19 shows a measurement set-up used for a measurement of size distribution and mass and further calculation of deagglomeration and flow rate.

## DESCRIPTION

In a starting step 100 of Figure 1 an electrostatically dosed electro-powder is brought into a powder dose analysis step 110. Dosing parameters are then determined in a step 120 to finally result in an electro-dose in a step 160. Electro-powder here is defined as a prepared active substance meeting a set of electrical specifications for optimum electrostatic dosing properties. Specific charge is expressed in Coulomb per mass unit in this context as $\mu C/g$ after charging. Such an electro-powder should present an absolute specific charge, after charging by induction, corona, or tribo-charging, of the order of 0.1 to 25 $\mu C/g$ ($0.1\times10\text{-}6$ – $25\times10\text{-}6$ Coulomb/gram of negative or positive charge) and a discharge rate constant $Q_{50} > 0.1$ sec. $Q_{50}$ is defined as the time until 50% of the electrostatic charge is discharged, (for instance after a corona charging in an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD). Furthermore the electro-powder should constitute a powder with more than 50 % of fine particle fraction with a particle size less than 5 μm and have a water content of less than 4 % together with a water activity $a_w < 0.5$, preferably being between 0.2 and 0.3 and a tap density of less than 0.8 g/ml.

Water content is defined as the amount of weakly bound water. It's calculated as the difference between the total water content, determined e g by Karl-Fischer titration, and the amount of strongly bound water, e.g. crystal water, characteristic for the substance. Water activity $a_w$ is a dimensionless quantity, which may, for instance, be measured with an AquaLab model series 3 TE. Tap density is, for instance, measured by using a Dual Autotap from Quantachrome© Corporation according to British Pharmacopoeia for Apparent Volume method. Both water activity and tap density are quantities well know to a person skilled in the field of chemistry analysis.

All measurements are performed at room temperature defined as in a range of 18 - 25°C in air or nitrogen atmosphere with a relative humidity less than 5 %. The absolute specific charge is the charge the electro-powder presents after an electrostatic charging being performed and subsequently measured in μC/g with an electrometer, e.g. a Keithley Electrometer 6512 or an Electrical Low Pressure Impactor (ELPI) model 3935 from DEKATI LTD.

The electro-dose is then defined as an electrostatically dosed electro-powder possessing the following specification: Porosity defined as $Dp_{electro\text{-}dose} = 100 - 100(\ density_{electro\text{-}dose} / \ density_{electro\text{-}powder}\ ) > 75$ % and having a optimized de-agglomeration of > 25 % and more preferable being more than 50 % and most preferable more than 75 % and meeting a dosage uniformity according to USP 24-NF 19 Supplement 601 Aerosols/Physical Tests pages 2674 - 2688, which will hereafter be referred to as USP, and also possessing a de-agglomeration difference measured according to USP compared with the de-agglomeration at a flow representing a pressure drop over the inhaler device reduced to 1 kPa $(1 - (\text{de-agglomeration}(Q_{1kPa}) / \text{de-agglomeration}(Q)) \times 100) <$ 25 % and more preferably less than 10 % and most preferably less than 5 %.

Particles intended for the deep lung, here defined as the peripheral lung and alveoli, where direct transport of an active substance to the blood can take place, should have a particle size in the range 0.5 - 3 μm. For treatment in the local lung, defined as upper parts of the lung, where treatment normally takes place for instance in asthma treatment, the particle size should be in the range 3-5 μm. All particle sizes are defined as the size of the particles measured with for instance a laser diffraction instrument e.g. a Malvern Mastersizer for physical size classification or an Andersen Impactor for an aerodynamic size classification and if not stated otherwise always referred to as aerodynamic particle size.

The active substance is a pharmaceutical active chemical or biological substance intended for administration into the deep or upper lung airways by oral inhalation from a dry powder inhaler device (DPI), where inhaled

macromolecules could be from the following therapeutic areas: Insulin rapid intermediate and slow acting and diabetes peptides, interferons, interleukins and antagonists, antibodies, peptides for immune suppression, nerve growth factors, vaccines, gene therapies, genetically modified virons and/or bacterias, parathyroid hormone, osteoporosis peptides, antiobesity peptides, luteinizing hormone releasing hormone (LHRH) and LHRH analogs, somatostatin analogs, human calcitonin, colony stimulating factor, erythropoietins, growth hormones, erectile dysfunction, anti-pregnancy hormones.

The active substance also could be selected from the pharmaceutical active chemical and biological substances vasopressin, a vasopressin analogue, desmopressin, glucagon, corticotropin, gonadotropin, calcitonin, C-peptide of insulin, parathyroid hormone, human growth hormone, growth hormone, growth hormone releasing hormone, oxytocin, corticotropin releasing hormone, a somatostatin analogue, a gonadotropin agonist analogue, atrial natriuretic peptide, thyroxine releasing hormone, follicle stimulating hormone, prolactin, an interleukin, a growth factor, a polypeptide vaccine, an enzyme, an endorphin, a glycoprotein, a lipoprotein kinas, intra-cellular receptors, transcription factors, gene transcription activators/repressors, neurotransmitters (natural or synthetic), proteoglycans., a polypeptide involved in the blood coagulation cascade, that exerts its pharmacological effect systemically or any other polypeptide that has a molecular weight (Daltons) of up to 50 kDa or from the group consisting of proteins, polysaccharides, lipids, nucleic acids and combinations thereof or from the group consisting of leuprolide and albuterol or is among opiates or nicotine and nicotine derivates or scopolamin, morphine, apomorphine analoges or equivalent active substances or pharmaceutical active chemicals for asthma treatment, e.g. budesonid, salbutamol, terbutalinsulphate, salmeterol, flutikason, formoterol or salts thereof.

The first step **110** of the powder dose analysis includes a series of at least five powder doses to be analyzed in a step **210** illustrated in Figure 2.

Standard settings of the input parameters are then used, which are well spread over an interval to have a possibility to in a sequence of steps **220** to **270** determine the most important specifications regarding height, area, mass, porosity and dose de-agglomeration at flow rate Q according to USP and $Q_{1kPa}$. Very important is to determine if a porosity adjustment is necessary to be performed by active use of mechanical and/or electrical methods in the preparation of the electro-powder into an electro-dose by adjusting the dose porosity to an optimum giving an optimum inhalation performance regarding de-agglomeration. The porosity of the electro-dose is then defined as $D_p = 100 - 100 \times (\text{density}_{electro\text{-}dose} / \text{density}_{electro\text{-}powder})$ producing a measure in percent.

Dose height is then measured in step **220** for the powder doses of step **210** using for instance a Laser displacement sensor from Keyence LK-031 with electronics LK-2001 and cables LK-C2 giving the height of the powder bed in µm.

The electro-powder doses tested in step **210** are then brought to step **230** for dose area investigation, wherein the projected size of the powder dose onto the device member is measured with, e.g., a stereo microscope from Olympus and noted down in millimeters with a resolution of 100 µm.

A machine script is a program to control a sequence of operations inside a feeding device 45 in Figure 8, which is a device that in a controlled way is feeding electrostatically charged electro-powder into an electrical field allowing selected electro-powder particles with the right particle size to be transported to the device member and having a set of parameters added to the script to control the flexible settings of a powder dose. This electrostatic dosing device **45** is also performing a control of the absolute specific charge and all other essential parameters, e.g. feeding rate of de-agglomerated electro-powder by the machine script. The dose de-agglomeration step **240** is defined as breaking up agglomerated electro-powder by introducing electrical, mechanical, or aerodynamic energy. Usually de-agglomeration is

performed as a stage one during dosing of the electro-powder and as a final stage two during the patient's inspiration of the electro-dose through the DPI. De-agglomeration is measured, e.g. using a Malvern Mastersizer as an example of a laser diffraction instrument used to measure particle size distribution both in aerosols and in liquids for physical size classification or an Andersen Impactor for an aerodynamic size classification as described in USP.

Table I

| Dosing Time (s) | Vibration KHz; μm | Frequency $t_1;t_2;E_1;E_2$ s ; V | Electrical field E V/mm | Filter Potential $V_f$ | Machine Script |
|---|---|---|---|---|---|
| 8 | 0;0 | 0,5;0,01;250;-50 | 250 | 600 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;250;-50 | 250 | 600 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;250;-50 | 250 | 600 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;250;-50 | 250 | 600 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;250;-50 | 250 | 600 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;300;-50 | 300 | 650 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;350;-50 | 350 | 700 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;400;-50 | 400 | 750 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;500;-50 | 500 | 800 | Test QC 1 |
| 8 | 0;0 | 0,5;0,01;1000;- 50 | 1000 | 1000 | Test QC 1 |

The electro-powder de-agglomeration is performed in the electrostatic feeding device **45** where de-agglomeration and classifying of the electro-powder is performed then resulting in obtaining a majority of the powder particles being in the correct size range 0,5-5 μm for being dosed onto the device member. This de-agglomeration operation is referred to as de-agglomeration #1 or electro-powder de-agglomeration.

The electro-dose de-agglomeration or de-agglomeration #2 takes place when sucking off the electro-dose from the device member accompanied with a de-agglomeration of the dose in the mouthpiece.

De-agglomeration #2 is measured as two different airflow values, whereby the first airflow Q is according to USP and the second airflow $Q_{1kPa}$ is at a pressure drop over the inhaler device of 1 kPa. The two different airflow values are for determining if an increase in inhalation energy has a major effect on the de-agglomeration #2. It is important to minimize the effect of the inhalation energy by adjusting the de-agglomeration #2 and the dosing properties and de-agglomeration #1 to meet the electro-dose specification.

The electro-dose de-agglomeration is measured using a mouthpiece with a nozzle in the procedure which is identical to the construction and settings inside the DPI intended to be used and with a same device member as is to be used with the DPI. The portion at the end of the mouthpiece towards the device member has to be aerodynamically correctly constructed to minimize retention.

The de-agglomeration is then calculated using the electro-powder particle size specification as input material and the High Pressure Liquid Chromatography HPLC analysis regarding particle size distribution after a standard sucking off from the device member as the output result. The de-agglomeration of the electro-dose is then calculated as percent of de-agglomerated electro-dose at 3 µm, $DD_{3\mu m}$, and 5 µm, $DD_{5\mu m}$, compared to the amount of powder less than 3 µm and 5 µm in the original electro-powder. The de-agglomeration must be more than 25 % to meet the electro-dose specification. Fig 17 and fig 18 present calculations of de-agglomeration at 3µm and 5 µm, respectively, in a graphical representation marking the areas under the particle size distribution curves for the initial and resulting distributions respectively. The curves plotted with dots representing initial electro-powder size distribution and the curves plotted with squares representing resulting electro-dose size distribution.

The dose mass in step **250** is possible to be measured in two different ways. First option is to use a Malvern Mastersizer, where the powder is collected on a filter after analysis through the instrument. The filter is then possible to

analyze either using a balance, e.g. a Mettler Toledo UMT5 Ultra Microbalance or by chemical analyzes, e.g. a HPLC SpectraSYSTEM with a UV 6000 detector or any other suitable detector. A second option and also most preferable is to determine the powder mass using an Andersen Impactor and analyze both the aerodynamic particle size distribution and the total mass using for instance the HPLC SpectraSYSTEM with a UV 6000 detector in accordance with USP.

To meet the electro-dose specification the mass must conform to the uniformity of dose stipulated in the USP and more preferable be between 95 % < label claim < 105 % when this will be possible by a proper control regarding the electro-powder and the electrostatic dosing device together with the machine script.

Results from the above analysis: dose height in step **220**, dose area in step **230**, dose de-agglomeration in step **240** and dose mass in step **250** is noted down for calculations.

Dose density is calculated from dose mass in micrograms from step **250** divided by dose height in millimeters from step **220** and divided by dose area in $mm^2$ from step **230** and noted down as dose density in $\mu g/ mm^3$ in step **260**. Dose porosity in step **265** is here defined in percent as $D_p = 100 - 100 \times (\text{density}_{electro\text{-}dose}/\text{density}_{electro\text{-}powder})$ with the electro-powder density in this example being 1,4 $kg/dm^3$. Dose mass per dose area is calculated in step **270** as dose mass in µg from step **250** divided by dose area from step **230** and noted as $\mu g/mm^2$. The results are then combined with the settings presented in Table I and are presented with the results in Table II below.

Thus, all analytical results are noted down together with input data in an analytical report as step **280** forming a decision material for the step **120** of Figure 1 determining dosing parameters. The result of this example illustrates that, in order to obtain a high quality dose with respect to de-

agglomeration in step **240**, the dose porosity obtained at step **265** should be to approximately 98 % .

Table II

| Test | Dose height 220 µm | Dose area 230 mm² | Dose de-aggl. 240 3 µm % | Dose de-aggl. 240 5 µm % | Dose mass 250 µg | Dose density 260 µg/mm³ | Dose Porosity 265 % | Dose mass/area 270 µg/mm² |
|---|---|---|---|---|---|---|---|---|
| 1 | 196 | 40 | 80 | 82 | 77 | 9 | 99,4 | 1,9 |
| 2 | 92 | 40 | 81 | 84 | 73 | 20 | 98,6 | 1,8 |
| 3 | 76 | 40 | 81 | 85 | 75 | 25 | 98,2 | 1,9 |
| 4 | 64 | 40 | 84 | 87 | 78 | 30 | 97,9 | 2,0 |
| 5 | 69 | 40 | 83 | 89 | 77 | 28 | 98,0 | 1,9 |
| 6 | 124 | 40 | 77 | 84 | 173 | 35 | 97,5 | 4,3 |
| 7 | 137 | 40 | 74 | 81 | 214 | 39 | 97,2 | 5,4 |
| 8 | 148 | 40 | 66 | 73 | 365 | 62 | 95,6 | 9,1 |
| 9 | 135 | 40 | 63 | 68 | 415 | 77 | 94,5 | 10,4 |
| 10 | 124 | 40 | 58 | 64 | 520 | 105 | 92,5 | 13,0 |

The decision in step **120** determining dosing parameters is then used to make several powder dosing in a step **130** for tests and to verify that the chosen settings are correct and verified in a step **140** according to a repeated step of powder dose analysis. If the result of this powder dose analysis proves to be according to set specification for an electro-dose the settings is noted down for the continued manufacturing process.

On the other hand, if powder dosing according to step **130** results are not within set specification for an electro-dose, the result is in a step **145** returned to the step **120** of determining dosing and parameters for a new optimized parameter settings. The determining preparation of electro-dose as a step **310** in Figure 3 is then taking into account the specification of the electro-powder in step **300** and dosing parameters in step **320** to have a new set of tests for the preparation of the electro-dose. A very useful tool to optimize the electro-dose is to use a statistical planning method for the tests

to reduce the total amount of tests needed and fast finding the optimum preparation scheme for a desired electro-dose.

Figure 4 shows an illustrative cross section a device member with a dissipative or conductive carrier area **14** as a dose receiver for the electro-dose and an isolative material **10**, e.g. plastic, having a surface resistance greater than $10^{11}$ ohms.

Figure 5 illustrates a cross section with another material as walls where the dissipative or conductive material **11** has a potential defined through an applied voltage **12** and where a conductive material is a material with a surface resistance < $10^6$ ohms or a dissipative material with a surface resistance between the conductive and the isolative material $10^6$ < Dissipative material < $10^{11}$ohms.

Figure 6 shows in an illustrative cross section a device member with a dissipative or conductive material area **24** located under or behind a thin layer approximately 10-3000 μm of isolative material **10** and where the dissipative or conductive material is having a set potential through an applied voltage **12**.

Figure 7 shows an illustrative cross section of a device member with two separate dissipative or conductive materials **22** and **24** and a isolative material **10**, where the dissipative or conductive material **24** forms the dose receiver of the electro-dose through a applied voltage **12** attracting the electrostatically charged electro-powder and the conductive material **22** is a conductive or dissipative material for applying a second electrical field to guide the powder to the correct position through a second applied voltage **18**.

In a further illustrative embodiment similar to Figure 5 the device member material forming the dose carrier may be chosen from an isolative plastic material, which is processed before dosing by ionized air to remove

electrostatic charges from its surface. In another embodiment an isolative plastic material is processed before dosing by introducing the device member into humid air to remove electrostatic charge from its surface. In a third embodiment the device member isolative plastic material is processed before dosing by combination of ionized air and humid air to remove electrostatic charges from its surface.

In still a further embodiment the device member is temporarily given a dissipative surface by applying a thin solvent layer onto its surface, e.g. water, carbon dioxide or other non-toxic and FDA approved solvent. Such a solvent layer is then applied with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing removing the solvent from the device member.

Figure 8 shows in an illustrative example a dosing and metering set-up where a feeding device **45** for electrostatically charged electro-powder is subject to an electrical field **48** created by a separate applied potential **46** measured in V/mm and intended for transporting the electrostatically charged powder in a controlled way for dosing, metering or measuring purposes. A total field acts between the device member and the electro-powder feeder **45** through two different adjusted potentials **12** and **46**.Between the feeder **45** and the device member is situated a filter **44** to shield part of the device member not to be subject to dosing until the device member is in the correct position and then having a transportation of electrostatically charged electro-powder particles **49** metered onto the carrier portion of the device member.

Figure 9 shows an illustrative example a dosing and metering set-up with a device member **11** made from a dissipative material at which powder is dosed by an applied electrical field between the feeder of electrostatically charged electro-powder **45** and the device member utilizing an electrical filter **52** with a applied make-up potential to guide the powder to the correct position onto the carrier portion of the device member. The filter potential

also serves as a possibility to control depositing on and off in a simple way by switching the applied voltage to the filter between normal potential and a much lower potential compared to the potential applied to the device member in this example. The guiding of electrostatically charged electro-powder particles **49** is then a function of applied voltage of the feeder of electrostatically charged electro-powder **49** and the voltage applied to the device member **12** and the potential of the filter **52**. The filter **52** is supported by an isolative filter holding material **44**.

Figure 10 shows in an illustrative example a dosing and metering set-up with a device member **11** in a dissipative material dosed onto by an applied electrical field between the feeder **45** of electrostatically charged electro-powder and the device member utilizing an electrical filter **52** with an applied make-up potential **59** to guide the powder to the correct position at the carrier portion of the device member **11**. The filter potential also serves as a possibility to control deposition on and off in a simple way by changing the potential of the filter **52**. The guiding of electrostatically charged electro-powder particles **49** is then a function of applied voltage to the feeder **45** of electrostatically charged electro-powder and the applied voltage to the device member **11** and the potential of the filter **52**.The filter **52** is supported by an isolative filter holding material **44**. The dose is possible to measure during the dosing and metering operation by using the electrometer **66** and switching the voltage **65** in front of a high voltage generator **67**.During the dosing and metering operation it is also possible to control the density of the electro-dose by utilizing a mechanical vibration **64** or an electrical frequency utilizing , e.g. the switching box **65** resulting in a possibility to control the electrical field and the mechanical movement according to Figures 11 and 12.

Figure 11 shows an example of electrical fields $E_1$ and $E_2$ applied as alternating fields at a pre-selected frequency to have the electro-powder to "dance" at the device member **11** to thereby achieve an optimum porosity for an optimum of de-agglomeration according to Figure 16. Figure 11 shows

how the total dosing time period T is divided up in periods $t_1$ when the electrical field is at a maximum value of $E_1$ and other time periods $t_2$ when the electrical field is at a minimum value of $E_2$, whereby the time periods $t_1$ and $t_2$ are in the range $10^{-6} < t_1$, and $t_2 < 2$ seconds respectively.

Figure 12 illustrates an example of a set up with a mechanical vibration having a total dosing time period T and a maximum displacement of $D_1$ during $t_1$ and no displacement during the time period $t_2$ to make the dosed electro-powder particles to "dance" at the device member **11** and thereby, by means of a control of the applied field, having a controlled adjustment of the porosity to an optimum situation for an optimized de-agglomeration according to Figure 16, whereby the time periods $t_1$ and $t_2$ are in the range $10^{-6} < t_1$, and $t_2 < 2$ seconds, respectively.

Figure 13 shows a "tree" structure of powder particles at the device member **11** showing the ordering of particles of an electro-dose not being subject to adjustment of dose porosity disclosing chains of powder rising. from the device member. The electro-powder particles **72** are forming "trees" of particles resulting in an extremely high porosity. The porosity of an electro-dose is calculated using the width and height of the "tree" structure together with the length to calculate the volume and then dividing the mass of the electro-dose with the volume to obtain the density of the electro-dose. The porosity is then calculated as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ in percent, where the density of the electro-powder in this example is 1.4 kg/dm$^3$.

It should be noted that in the preferred process the carrier is turned with its receiving surface facing downwards as illustrated in Figures 13 to 15 when picking up the charged particles **72**, **82** or **92**. However, the process may also be performed as indicated by Figures 6 to 10.

Figure 14 shows an electro-dose on the device member **11** with a "sponge" structure defined as an intermediate structure of the electro-dose, where

some of the "tree" structures **82** have collapsed and are connected top to top forming a matrix with a medium to low density and less porosity through a adjusted density by electrical frequency or mechanical vibration during the dosing and metering operation thereby obtaining a lower porosity compared to the "tree" structure of Figure 13.

Figure 15 shows an electro-dose at a device member **11** presenting a velvet structure **92** after being porosity adjusted with the proper electrical frequency or mechanical vibration thereby obtaining a look like a smooth velvet cloth which shows much less porosity than the "sponge" structure.

Figure 16 illustrates the effect of a dose porosity adjustment in which the de-agglomeration of the electro-dose is measured at different porosities showing an optimum de-agglomeration both for particles less than 5 μm and for particles less than 3 μm having a porosity in the range marked as A also indicating that the electro-dose is independent of the flow at porosities inside the range A.

In the range marked B the de-agglomeration is in a transition area and showing medium flow dependence and a lower grade of de-agglomeration. In range C the porosity is lower and the powder much harder to de-agglomerate in dose de-agglomeration and also showing a strong dependence of the flow i.e. the energy level of the de-agglomeration #2 and are not suitable as an dose for inhalation and subject to optimization. $DD_{5\mu m}$ is the dose de-agglomeration at 5 μm and at a differential pressure according to USP and $DD_{1kPa}$ is also according to USP but at a pressure drop over the inhaler of 1kPa.

Measurement of de-agglomeration is performed, e.g., according to Figure 19, using an Andersen Inpactor together with a mouthpiece and a device member in a set-up identical with the intended DPI for the electro-dose or instead of the Andersen Impactor using a Malvern Master Sizer S to measure the physical particle size. When the particle distribution is measured the de-

agglomeration can be calculated knowing the electro-powder particle size distribution.

The de-agglomeration is measured at two different rates of flow, flow-rate Q according to USP and at a flow-rate at 1 kPa pressure drop over the inhaler device according to USP. Measuring at two different flow-rates indicates if the electro-dose in the intended DPI is flow dependent or flow independent, as this may be an important aspect for the patient. If the difference in de-agglomeration is less than 25 %, when calculated as (*100* - *100*×(de-agglomeration($Q_{1kPa}$)/de-agglomeration(Q)), then the electro-dose meets the specifications, if the result is outside the electro-dose specifications further optimization of the electro-dose has to be performed by going back to step **310**.

Figure 17 describes how the de-agglomeration at 3 μm is calculated using the initially input electro-powder under 3 μm represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the second area with the calculated value of the surface of the first area and multiplying by a factor 100 the de-agglomerated amount below 3 μm is obtained in percent.

Figure 18 describes how the de-agglomeration at 5 μm is calculated using the initially input electro-powder under 5 μm represented by the hatched area as a base. The amount of de-agglomerated electro-powder from the electro-dose is then represented by the dark area under the curve showing resulting powder. By dividing the calculated value of the surface of the second area in Figure 18 with the calculated value of the surface of the first area in Figure 18 and multiplying by a factor 100 the de-agglomerated amount below 5 μm is obtained in percent.

Figure 19 illustrates an example of a de-agglomeration and mass measurement set-up **71** identical to the inhaler to be used to determine the particle size distribution and mass from a pre-metered electro-dose sucked up from the device member **73** through a mouthpiece **78** using an Andersen Impactor **74** to determine the particle size distribution. The total pressure drop over the de-agglomeration set-up is measured with the pressure gauge **75** and the flow-rate of the air is measured with a flowmeter **76** in liters/minute. Suction may be achieved by means of a pumping device **77**.

All measurements of the particle size distribution is measured at two different pressure drops over the inhaler device first all measurements are the performed according to USP and only the pressure is changed for the measurement at a lower pressure 1kPa over the inhaler device **71** in point **79**.

A complementary particle size distribution is also measured at 1kPa pressure drop over the de-agglomeration #2 set-up **71** indicated by the pressure gauge **79** as diffirential pressure to the atmosphere and then the obtained flow rate is noted down and named $Q_{1kPa}$ .The particle size distribution obtained at the flow rate $Q_{1kPa}$ is the compared with the particle size distribution obtained at the flow rate Q. the flow rate obtained by using all other settings according to the USP, and naming this flowrate $Q_{1kPa}$ and the resulting calculated The result of the test of de-agglomeration #2 at two different pressures over the inhaler device and compared according to fig 16 to determine if the result meets the specification for an electro-dose and also if the de-agglomeration for 3 and 5 μm, $DD_{3\mu m,1kPa}$ and $DD_{5\mu m,1kPa}$ are within the specifications of the medical drug.

Thus the method and process according to the present disclosure will result in a very well defined electro-dose for utilization in a dry powder inhaler resulting in a small standard deviation of the doses for repeated administrations.

It will be understood by those skilled in the art that various modifications and changes may be made to the present invention without departure from the scope thereof, which is defined by the appended claims.

# CLAIMS

1. An electro-dose constituting a medical powder intended for use in a dry powder inhaler, said electro-dose being prepared from an electro-powder constituting an active powder substance or a dry powder medical formulation, which is metered onto a device member forming a dose carrier, giving a fine particle fraction (FPF) presenting of the order 50 % or more of its content with a particle size between 0.5-5 μm, the dose further presenting an optimized porosity of 75 to 99.9 %.

2. The electro-dose according to claim 1, said metered electro-dose constituting an electro-powder providing electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 μC/g and presents a charge decay rate constant $Q_{50}$ of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity $a_w$ of less than 0.5.

3. The electro-dose according to claim 1, said metered electro-powder after a mechanical vibration of the dose receiving device member during a metering operation being adjusted to a porosity presenting a value in percent between 75 and 99.9.

4. The electro-dose according to claim 1, said metered electro-dose, after analysis by a laser triangular method for a total volume calculation and a HPLC or weighing operation for determining the electro-dose mass, the porosity of the electro-dose, calculated in percent as $100 - 100\times(\text{Density}_{\text{electro-dose}}/\text{Density}_{\text{electro-powder}})$, presenting a value in percent between 75 and 99.9.

5. The electro-dose according to claim 1, said metered electro-dose having, onto a surface area of said device member which forms a dose carrier, a height less than 800 μm.

6. The electro-dose according to claim 1, said metered electro-dose by using mechanical vibrations of the device member being adjusted to a porosity having in percent a value between 75 and 99.9.

7. The electro-dose according to claim 1, said metered electro-dose, by using a frequency oscillation in an electrical field, being adjusted to a porosity having in percent a value between 75 and 99.9.

8. A method for preparing a metered electro-dose of electro-powder for administration into the deep or upper lung airways by oral inhalation by a dry powder inhaler device, comprising the steps of:

dosing a medical powder, being a preparation of chemical and biological substance forming an electro-powder onto a device member constituting a dose carrier

forming of a metered electro-dose bed onto said dose carrier using electrical field technology;

combining said electrical field technology with a mechanical vibration and/or an applied electrical frequency;

analyzing said metered electro-dose bed regarding dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity;

comparing analysis result with predefined dosing parameters for deciding that said metered electro-dose on the dose carrier complies with basic requirements for administration by the inhaler.

9. The method according to claim 8, comprising the further step of controlling that said metered electro-dose has an optimized porosity of 75 to 99.9 %.

10. The method according to claim 8, comprising the further step of utilizing mechanical vibration of the dose receiving device member during dosing operation to adjust said metered electro-dose powder porosity to an optimized value in percent between 75 and 99.9.

11. The method according to claim 8, comprising the further step of analyzing said metered electro-dose by a laser triangular method and a HPLC or weighing operation for a total volume calculation to determine

electro-dose mass in order to calculate the electro-dose powder porosity in percent as $D_p = 100 - 100 \times (\text{density}_{\text{electro-dose}} / \text{density}_{\text{electro-powder}})$ obtaining an optimized value in percent between 75 and 99.

12. The method according to claim 8, comprising the further step of preparing said metered electro-dose onto a surface area of said device member, to obtain an electro-dose height of less than 800 μm.

13. The method according to claim 12, comprising the further step of controlling said metered electro-dose height by means of a triangular laser measuring instrument.

14. The method according to claim 8, comprising the further step of additionally preparing said metered electro-dose by using an oscillating electrical field to adjust the porosity of said electro-dose to an optimized value in percent of 75 to 99.9.

15. The method according to claim 8, comprising the further step of preparing said electro-dose using at least one active electrical filter with a control potential switched on and off within a voltage range $V_{\text{low electrical field}} \leq V_{\text{filter}} \leq V_{\text{device member}}$ during a metering process and using an opening area per controlled opening of the active electrical filter in a range of $0.02 \leq$ Filter opening $\leq 75$ mm$^2$.

16 The method according to claim 8, comprising the further step of measuring metered electro-dose mass by draining its electrostatic charge into a electrometer thereby to determine a specific charge in $\mu C / g_{\text{electro-powder}}$ .

17 The method according to claim 8, comprising the further step of measuring metered electro-dose height using a contrast analyzing method and controlling height of said electro-dose to be less than 800 μm.

18 The method according to claim 8, comprising the further step of measuring metered electro-dose height using a laser triangulation method and controlling height of said electro-dose to be less than 800 μm.

19 The method according to claim 8, comprising the further step of measuring metered electro-dose height using a image analyzing method and controlling height of said electro-dose to be less than 800 μm.

20 The method according to claim 8, comprising the further step of measuring metered electro-dose height using a combination of image analysis, laser triangulation, contrast methods to ensure a height of said electro-dose to be less than 800 μm.

21 The method according to claim 8, comprisning the further step of measuring electro-dose deagglomeration using a Andersen Impactor for aerodynamic particle size distribution or a Malvern Mastersizer S to determine a physical particle size distribution for a calculation and optimization of deagglomeration of said electro-dose by changing its porosity.

22. A process of preparing doses of powder to be used for administration by a dry powder inhaler, wherein

a medical powder, being a preparation of a chemical and/or biological substance forming an electro-powder, is metered onto a device member constituting a dose carrier thereby forming a metered electro-dose;

a metered electro-dose bed is formed on a dose carrier material using electrical field technology;

obtained metered electro-dose bed is analyzed regarding dose height, dose area, dose de-agglomeration, dose mass, dose density, dose porosity; and

a result of the analysis is compared with predefined dosing parameters for deciding that the prepared metered electro-dose of powder on the dose carrier complies with the basic requirements for administration by the inhaler.

23. The process according to claim 22, wherein electrical field technology is combined with a mechanical vibration and/or an applied electrical frequency.

24. The process according to claim 22, wherein a material of said device member is an isolative plastic material processed before dosing and metering by ionized air to remove electrostatic charges from its surface.

25. The process according to claim 22, wherein a material of said device member is an isolative plastic material processed before dosing and metering by introducing the device member into humid air to remove electrostatic charge from its surface.

26. The process according to claim 22, wherein a material of said the device member is an isolative plastic material processed before dosing and metering by combination of ionized air and humid air to remove electrostatic charges from its surface.

27. The process according to claim 22, wherein said electro-conductive material is mixed into a plastic material constituting the device member.

28. The process according to claim 22, wherein said electro-conductive material is coated onto a plastic material constituting the device member.

29. The process according to claim 27, wherein said conductive material and the plastic material combination of said device member has a specification presenting a surface resistance of $10^3$ - $10^{12}$ Ω, and a volume resistivity of $10^3$ - $10^{12}$ ohm·m.

30. The process according to claim 28, wherein said conductive material and the plastic material combination of said device member has a specification presenting a surface resistance of $10^3$ - $10^{12}$ Ω, and a volume resistivity of $10^3$ - $10^{12}$ ohm·m.

31. The process according to claim 22, wherein said electro-conductive material used for said device member is obtained from any of materials such as silver powder, platinum powder, gold powder, stainless steal powder, antimony-doped tin oxide, antimony-doped silica oxide, or is a X-doped silica where X is an adamantine semiconductor, e.g., Ge , Zno, GaSb or an octahedral semiconductor, e.g. SnSE, AgSbSe2, InSb or carbon or any other electro-conductive material approved by FDA and possible to incorporate into plastics.

32. The process according to claim 22, wherein said device member is temporarily given a dissipative surface by applying a thin solvent layer onto its surface e.g. water, carbon dioxide or other non-toxic and FDA approved solvent with appropriate electrical properties by using a temperature difference or a high humidity chamber and after dosing and metering removing said solvent from said device member.

## ABSTRACT

An electro-dose and a method and a process for obtaining an electro-dose are disclosed. The electro-dose constitutes a metered medical powder and is formed from an electro-powder constituting an active powder substance or a dry powder medical formulation being transferred onto a device member forming a dose carrier. The electro-dose prepared from an electro-powder presents a fine particle fraction (FPF) having of the order 50 % or more of its content with a particle size between 0.5-5 μm. The electro-powder of such a metered electro-dose further provides electrostatic properties regarding absolute specific charge per mass after charging of the order 0.1 to 25 μC/g and presents a charge decay rate constant $Q_{50}$ of more than 0.1 sec with a tap density of less than 0.8 g/ml and a water activity $a_w$ of less than 0.5.

The electro-dose porosity is adjusted by means of mechanical and/or electrical vibration of the dose receiving device member during the electro-dose build-up operation to obtain an optimized porosity value in percent of 75 to 99.9 calculated as $100 - 100 \times (\text{Density}_{\text{electro-dose}} / \text{Density}_{\text{electro-powder}})$. The method and the processing of electro-doses is partly illustrated by a flow-chart in which steps 220 to 270 present parameters necessary to be kept under strict control.


(Fig. 2)


100
Electro-powder
110
Powder dose analysis
120
Determining dosing parameters
130
Powder dosing
140
Powder dose analysis
150
Approved ?
160
Electro-dose
145

Fig. 1


200
Powder dose analysis
210
Powder dosing
220
Dose height
230
Dose area
240
Dose de-agglomeration
250
Dose mass
260
Dose density
265
Dose porosity
270
Dose mass/area
280
Analytical report

Fig. 2


300
Electro-powder
310
Determining preparation of electro-dose
330
Powder dose analysis
340
Electro-dose
320
Time
Vibrations
Frequency
Electrical field
Filter potential

Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig.10




Fig. 11




Fig. 12




Fig. 13




Fig. 14


11
92

Fig. 15


DD5 µm
DD5 µm, 1kPa
C
B
A
DD3 µm
DD3 µm, 1kPa
De-agglomeration 3 µm and 5 µm in %
0
0
Dose porosity %

Fig. 16


Mass %
• Initial powder
▪ Resulting powder
0 1 2 3 4 5 6 7 8 9
Particle size µm

Fig. 17


Mass %
• Initial powder
▪ Resulting powder
0 1 2 3 4 5 6 7 8 9
Particle size µm

Fig. 18




Fig. 19

Ref. P239US00AH/IO

# COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**Metered electro-dose**

the specification of which: *(check one)*

**REGULAR OR DESIGN APPLICATION**

[X] is attached hereto.

[ ] was filed on as application Serial No. and was amended on (if applicable).

**PCT FILED APPLICATION ENTERING NATIONAL STAGE**

[ ] was described and claimed in International application No. filed on and as amended on (if any).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

**PRIORITY CLAIM**

I hereby claim foreign priority benefits under 35 USC 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

**PRIOR FOREIGN APPLICATION(S)**

| Country | Application Number | Date of Filing (day, month, year) | Priority Claimed |
|---|---|---|---|
| Sweden | 0003082-5 | August 31, 2000 | yes |
| | | | |

*(Complete this part only if this is a continuing application.)*

I hereby claim the benefit under 35 USC 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 USC 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

| (Application Serial No.) | (Filing Date) | (Status–patented, pending, abandoned) |
|---|---|---|

## POWER OF ATTORNEY

*The undersigned hereby authorizes* the U.S. attorney or agent named herein to accept and follow instructions from **Aros Patent AB** as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

As a named inventor, I hereby appoint the registered patent attorneys represented by Customer No. **000466** to prosecute this application and transact all business in the Patent and Trademark Office connected therewith, including: **Robert J. PATCH, Reg. No. 17,355, Andrew J. PATCH, Reg. No. 32,925, Robert F. HARGEST, Reg. No. 25,590, Benoît CASTEL, Reg. No. 35,041, Eric JENSEN, Reg. No. 37,855, Thomas W. PERKINS, Reg. No. 33,027, and Roland E. LONG, Jr., Reg. No. 41,949,**

c/o YOUNG & THOMPSON,
Second Floor,
745 South 23rd Street,
Arlington, Virginia 22202.

00466
PATENT .TRADEMARK OFFICE

Address all telephone calls to Young & Thompson at 703/521-2297. Telefax: 703/685-0573.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: **Thomas NILSSON**
*(given name, family name)*

Inventor's signature _____ Date 000911

Residence: **Mariefred, Sweden** Citizenship: **Swedish**

Post Office Address: **Hagavagen 3**
**647 32 Mariefred, Sweden**

Full name of second joint inventor, if any: **Lars-Gunnar NILSSON**
*(given name, family name)*

Inventor's signature _____ Date 000911

Residence: **Koping, Sweden** Citizenship: **Swedish**

Post Office Address: **Esplanaden 15E**
**731 30 Koping, Sweden**